What is KRRO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.15B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KRRO?

P/E (TTM) is n/a and 52-week range is $5.20 to $55.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KRRO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KRRO?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-3.58B, EPS (TTM) near $-10.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Korro Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 14.4M shares outstanding, ISIN US5009461089 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Korro Bio Inc

$KRRO

Health Care · Biotechnology

IR Run Scenarios

$10.16

-3.97%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Employees

Website

www.korrobio.com/

IPO

2019-10-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)